Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
At the Myeloma 2015 meeting, Prof Michele Cavo (Bologna University School of Medicine, Bologna, Italy) discusses the heterogeneity and treatment recommendations for high-risk multiple myeloma. Emerging therapeutic strategies in clinical development, including lenalidomide and bortezomib-based treatment regimens, are showing promising activity for this patient group.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.